Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Liraglutide? Benefits, Research & Safety
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Also known as:
Victoza
Saxenda
NN2211
UK summary: Licensed UK medicine (Saxenda for weight management; Victoza for type 2 diabetes). Prescription-only. Daily injection; pre-dates and is generally less potent than semaglutide and tirzepatide. Lawful supply requires a UK prescriber and a regulated pharmacy.
Quick Facts
Category
GLP-1 Agonists
Half-Life
Approximately 13 hours
UK Status
MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
EU Status
EMA approved for both indications.
Overview
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It was one of the first long-acting GLP-1 analogues, sharing 97% sequence homology with native human GLP-1 but with modifications that extend its duration of action to allow once-daily dosing.
Like native GLP-1, liraglutide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. These effects make it effective for both blood glucose management in type 2 diabetes and weight reduction in obesity.
Liraglutide is marketed under two brand names: Victoza for type 2 diabetes treatment (at doses up to 1.8 mg daily) and Saxenda for chronic weight management (at 3.0 mg daily). Both formulations require once-daily subcutaneous injection.
While semaglutide has since become more prominent due to its greater weight loss efficacy and weekly dosing, liraglutide remains an important option with a longer track record of clinical use and extensive safety data from years of widespread use.
Evidence standards summary
Liraglutide — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
AStrong human evidenceOverall grade against our evidence grading methodology.
Licensed UK medicine (Saxenda for weight management; Victoza for type 2 diabetes). Prescription-only. Daily injection; pre-dates and is generally less potent than semaglutide and tirzepatide. Lawful supply requires a UK prescriber and a regulated pharmacy.
02Human evidence grade
AStrong human evidenceStrength of evidence from published human trials.
03Preclinical evidence grade
AStrong human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
- EU: EMA approved for both indications.
- Notes: Liraglutide is a fully approved prescription medication available through legitimate medical channels.
05Approved medical uses
- Type 2 diabetes (Victoza — MHRA-licensed POM).
- Chronic weight management in adults with BMI ≥ 30 or ≥ 27 with weight-related comorbidity (Saxenda — MHRA-licensed POM).
- Chronic weight management in adolescents aged 12-17 with obesity (Saxenda — MHRA-licensed POM).
06Unapproved / promotional claims
- Available without prescription from EU pharmacies.
- Same effect as semaglutide for less money.
- Safe to self-administer without medical supervision.
- Compounded versions are equivalent to the licensed product.
07Common internet claims
- Marketed by online sellers as a cheaper Wegovy alternative.
- Sold via grey-market routes that bypass UK prescription requirements.
- Promoted in 'compounded liraglutide' forms by some online clinics.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved by MHRA for weight management” | A | Yes | Low | Liraglutide is licensed in the UK as Saxenda for chronic weight management in eligible patients; Victoza is licensed for type 2 diabetes. |
| “Same effect as semaglutide for less money” | C | Yes | Moderate | Head-to-head data suggest liraglutide produces less weight loss than semaglutide and requires daily injections rather than weekly. |
| “Available without prescription from EU pharmacies” | E | No | High | Liraglutide is a UK POM; the UK supply route requires a UK prescription and regulated pharmacy. |
09Safety uncertainty score
Moderate
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- GI side effects (nausea, vomiting, diarrhoea) — common, dose-related.
- Pancreatitis (rare; class effect for GLP-1 agonists).
- Gallbladder disease (accelerated by rapid weight loss).
- Thyroid C-cell tumours (theoretical class warning; rodent finding, uncertain human relevance).
11Drug-interaction uncertainty
Moderate
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
WADA: Sport status unclearWADA strict-liability framing applies.
13UK legal position
UK: Prescription-only (UK POM)
MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
14EU legal position
EMA approved for both indications.
15What this page cannot tell you
- Whether a non-UK-prescription source supplies genuine, properly-stored product.
- Whether liraglutide is the right GLP-1 for your particular situation (semaglutide / tirzepatide may be preferred).
- Optimal duration and post-discontinuation management.
- Whether 'compounded liraglutide' from an online clinic meets sterility and identity standards.
16Last reviewed
17Citation quality score
AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- Long-term cardiovascular outcomes beyond LEADER trial endpoints.
- Optimal weight-management duration and stopping rules.
- Real-world cost-effectiveness against newer GLP-1s in NHS settings.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS specialist or GMC-registered private prescriber where higher efficacy is required.
- Continued lifestyle intervention via NHS Tier 2 weight-management programmes.
- Bariatric assessment for patients meeting NICE criteria.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I better suited to liraglutide or a weekly GLP-1 such as semaglutide?
- What is the dose-escalation schedule and side-effect plan?
- Is NHS access realistic for my situation, or is private the route?
- How will we monitor progress and when would we stop?
- What should I do if I want to stop the medicine?
Discovery & History
Liraglutide was developed by Novo Nordisk in the late 1990s and early 2000s as part of the company's GLP-1 research programme. The development was based on understanding that native GLP-1, while therapeutically promising, was rapidly degraded in the body with a half-life of only 1-2 minutes.
The key innovation was the acylation of GLP-1 with a fatty acid chain, enabling the molecule to bind non-covalently to albumin. This dramatically extended its half-life to approximately 13 hours, making once-daily injection practical.
Liraglutide received FDA approval for type 2 diabetes (as Victoza) in 2010 and EMA approval followed. It was one of the most successful diabetes drug launches, demonstrating both glycaemic and cardiovascular benefits.
In 2014, the FDA approved a higher dose of liraglutide (3.0 mg daily) as Saxenda for chronic weight management. This followed the SCALE clinical trial programme demonstrating significant weight loss in people with obesity.
The LEADER cardiovascular outcomes trial, published in 2016, demonstrated that liraglutide reduced the risk of major adverse cardiovascular events in high-risk patients with type 2 diabetes, adding an important benefit to its profile.
Mechanism of Action
Liraglutide activates GLP-1 receptors to produce multiple metabolic effects:
**Glucose-Dependent Insulin Secretion**
Liraglutide stimulates insulin release from pancreatic beta cells only when blood glucose is elevated, reducing hypoglycaemia risk compared to some other diabetes treatments.
**Glucagon Suppression**
The peptide inhibits inappropriate glucagon secretion from pancreatic alpha cells, particularly in the postprandial state, improving glucose control.
**Gastric Emptying Delay**
Liraglutide slows the rate at which food leaves the stomach, contributing to improved post-meal glucose levels and enhanced feelings of fullness.
**Central Appetite Suppression**
GLP-1 receptors in the hypothalamus and brainstem mediate appetite-reducing effects. Liraglutide reduces hunger and promotes satiety, leading to decreased caloric intake.
**Cardiovascular Effects**
Through mechanisms not fully understood but likely involving direct effects on the heart and vasculature as well as improved metabolic parameters, liraglutide provides cardiovascular protection.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved glycaemic control with HbA1c reductions of 1-1.5%
- 2Weight loss averaging 5-8% of body weight (Saxenda dose)
- 3Reduced cardiovascular events in high-risk patients (LEADER trial)
- 4Decreased systolic blood pressure
- 5Improved beta cell function markers
- 6Reduced appetite and food cravings
- 7Improved lipid profiles
Claim vs Evidence
How popular claims about Liraglutide stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved by MHRA for weight management” | A | Yes | Low | Liraglutide is licensed in the UK as Saxenda for chronic weight management in eligible patients; Victoza is licensed for type 2 diabetes. |
| “Same effect as semaglutide for less money” | C | Yes | Moderate | Head-to-head data suggest liraglutide produces less weight loss than semaglutide and requires daily injections rather than weekly. |
| “Available without prescription from EU pharmacies” | E | No | High | Liraglutide is a UK POM; the UK supply route requires a UK prescription and regulated pharmacy. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Diabetes: 0.6-1.8 mg daily; Obesity: up to 3.0 mg daily |
| Frequency | Once daily subcutaneous injection |
| Duration | Long-term treatment; gradual dose escalation over several weeks |
| Notes | Liraglutide is a prescription medication requiring medical supervision. Doses are typically escalated gradually to minimise gastrointestinal side effects. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (once daily)
| Half-Life | Stability |
|---|---|
| Approximately 13 hours | Pens should be refrigerated before first use; can be kept at room temperature for up to 30 days after first use |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (especially during initiation)
- Vomiting
- Diarrhoea
- Constipation
- Headache
- Decreased appetite
- Injection site reactions
Rare Risks & Concerns
- Pancreatitis
- Gallbladder disease
- Thyroid tumours (based on rodent studies)
- Hypoglycaemia (especially with concurrent insulin or sulfonylureas)
- Acute kidney injury
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- History of pancreatitis
- Pregnancy and breastfeeding
- Type 1 diabetes
UK & EU Regulatory Context
🇬🇧 United Kingdom
MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
🇪🇺 European Union
EMA approved for both indications.
Liraglutide is a fully approved prescription medication available through legitimate medical channels.
Clinical Studies Summary
LEADER: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Demonstrated 13% reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
N Engl J Med. 2016;375(4):311-322View on PubMed
SCALE Obesity and Prediabetes: A Randomized, Double-blind, Placebo-controlled Trial
Showed 8% weight loss with liraglutide 3.0 mg vs 2.6% with placebo over 56 weeks.
N Engl J Med. 2015;373(1):11-22View on PubMed
Looking for Liraglutide?
Source research-grade Liraglutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Liraglutide
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I better suited to liraglutide or a weekly GLP-1 such as semaglutide?
- What is the dose-escalation schedule and side-effect plan?
- Is NHS access realistic for my situation, or is private the route?
- How will we monitor progress and when would we stop?
- What should I do if I want to stop the medicine?
UK regulatory & safety context
Related Research Guides
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn more